Exelixis | EXEL - Capital Ordinário





Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
Amgen USD 540M 1000K 2026-03
AstraZeneca USD 1.55B 44K 2026-06
Bayer EUR 982.42M 0 2025-12
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cytokinetics USD 124.43M 2.17M 2026-03
Eisai JPY 282.11M 0 2026-03
Eli Lilly USD 943.5M 3.33M 2026-03
Exelixis USD 253.7M 8.78M 2026-03
Genmab DKK 61.62M 52K 2025-12
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
MacroGenics USD 63.56M 241K 2026-03
Merck USD 2.47B 12.72M 2025-12
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novartis USD 1.9B 7.38M 2026-06
Pfizer USD 5.7B 13M 2026-03
Puma Biotechnology USD 5K 0 2024-06
Sanofi EUR 1.2B 16.88M 2026-03
Takeda JPY 1.58B 460K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Xencor USD 74.06M 2.19M 2026-03